WallStreetZenWallStreetZen

NASDAQ: HUMA
Humacyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HUMA

Based on 3 analysts offering 12 month price targets for Humacyte Inc

Min Forecast
$15.00+934.48%
Avg Forecast
$19.00+1,210.34%
Max Forecast
$25.00+1,624.14%

Should I buy or sell HUMA stock?

Based on 3 analysts offering ratings for Humacyte Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although HUMA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates HUMA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their HUMA stock forecasts and price targets.

HUMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31
lockedlocked$00.00+00.00%2025-03-12
lockedlocked$00.00+00.00%2024-12-23

1 of 1

Forecast return on equity

Is HUMA forecast to generate an efficient return?

Company
-23.56%
Industry
142.9%
Market
80.27%
HUMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HUMA forecast to generate an efficient return on assets?

Company
9%
Industry
35.65%
HUMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HUMA earnings per share forecast

What is HUMA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.49
Avg 3 year Forecast
-$0.24

HUMA revenue forecast

What is HUMA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$9.7M
Avg 2 year Forecast
$88.7M
Avg 3 year Forecast
$165.9M

HUMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HUMA$1.45$19.00+1,210.34%Strong Buy
ALMS$4.14$23.00+455.56%Buy
NGNE$15.00$54.00+260.00%Buy
PRME$1.73$13.50+680.35%Strong Buy
RZLT$3.76$11.67+210.29%Buy
View Top Biotech Stocks

Humacyte Stock Forecast FAQ

Is Humacyte Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.

Out of 3 analysts, 2 (66.67%) are recommending HUMA as a Strong Buy, 1 (33.33%) are recommending HUMA as a Buy, 0 (0%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.

If you're new to stock investing, here's how to buy Humacyte stock.

What is HUMA's earnings growth forecast for 2025-2027?

(NASDAQ: HUMA) Humacyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Humacyte's earnings in 2025 is -$148,701,000.On average, 4 Wall Street analysts forecast HUMA's earnings for 2025 to be -$106,644,186, with the lowest HUMA earnings forecast at -$124,095,053, and the highest HUMA earnings forecast at -$93,071,290. On average, 2 Wall Street analysts forecast HUMA's earnings for 2026 to be -$75,232,626, with the lowest HUMA earnings forecast at -$85,315,349, and the highest HUMA earnings forecast at -$65,149,903.

In 2027, HUMA is forecast to generate -$37,228,516 in earnings, with the lowest earnings forecast at -$37,228,516 and the highest earnings forecast at -$37,228,516.

What is HUMA's revenue growth forecast for 2025-2027?

(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Humacyte's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $1,497,672,168, with the lowest HUMA revenue forecast at $1,102,894,782, and the highest HUMA revenue forecast at $1,892,449,555. On average, 2 Wall Street analysts forecast HUMA's revenue for 2026 to be $13,753,609,821, with the lowest HUMA revenue forecast at $6,922,952,758, and the highest HUMA revenue forecast at $20,584,266,883.

In 2027, HUMA is forecast to generate $25,731,884,792 in revenue, with the lowest revenue forecast at $14,095,646,810 and the highest revenue forecast at $37,368,122,774.

What is HUMA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: HUMA) forecast ROA is 9%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is HUMA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $19.00, with the highest HUMA stock price forecast at $25.00 and the lowest HUMA stock price forecast at $15.00.

On average, Wall Street analysts predict that Humacyte's share price could reach $19.00 by Mar 31, 2026. The average Humacyte stock price prediction forecasts a potential upside of 1,210.34% from the current HUMA share price of $1.45.

What is HUMA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: HUMA) Humacyte's current Earnings Per Share (EPS) is -$1.26. On average, analysts forecast that HUMA's EPS will be -$0.69 for 2025, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.60. On average, analysts forecast that HUMA's EPS will be -$0.49 for 2026, with the lowest EPS forecast at -$0.55, and the highest EPS forecast at -$0.42. In 2027, HUMA's EPS is forecast to hit -$0.24 (min: -$0.24, max: -$0.24).

What is HUMA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: HUMA) forecast ROE is -23.56%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.